ABSTRACT
Objective To investigate the relationship between serum HBV -DNA quantitative detection level and liver function markers and hepatitis B markers in patients with chronic hepatitis B virus. Methods The clinical data of 80 patients with chronic hepatitis B virus infection were retrospectively analyzed,and the HBV-DNA load,the serum hepatitis B markers and liver function indicators of the patients were detected and recorded. Another 80 cases received normal physical examination were selected as the control group. The serum markers were detected in both two groups. Results Of 80 patients with chronic hepatitis B virus infection,the positive rate of HBV-DNA was 45. 0% (36/80) and the detection rate of HBeAg was 30. 0% (24/80). The positive rate of HBV -DNA was positively correlated with HBeAg positive rate(χ2 =12. 46,P=0. 00). The levels of alanine aminotransferase (ALT),α-L-fucosidase (AFU),aspartate aminotransferase (AST) and plasma prothrombin time (PT) in HBV-DNA positive patients were significantly higher than those in HBV-DNA negative group( F=42. 693,18. 752,32. 692, 48. 225,all P=0. 000);and with the increase of the amount of virus,the level of the patients' index continued to increase. Conclusion For patients with chronic hepatitis B,the HBV-DNA level and the viral replication should be detected,and the liver function should be evaluated to observe the liver damage timely,thus to provide reference for clinical effective intervention.
ABSTRACT
Objective To investigate the relationship between serum HBV -DNA quantitative detection level and liver function markers and hepatitis B markers in patients with chronic hepatitis B virus. Methods The clinical data of 80 patients with chronic hepatitis B virus infection were retrospectively analyzed,and the HBV-DNA load,the serum hepatitis B markers and liver function indicators of the patients were detected and recorded. Another 80 cases received normal physical examination were selected as the control group. The serum markers were detected in both two groups. Results Of 80 patients with chronic hepatitis B virus infection,the positive rate of HBV-DNA was 45. 0% (36/80) and the detection rate of HBeAg was 30. 0% (24/80). The positive rate of HBV -DNA was positively correlated with HBeAg positive rate(χ2 =12. 46,P=0. 00). The levels of alanine aminotransferase (ALT),α-L-fucosidase (AFU),aspartate aminotransferase (AST) and plasma prothrombin time (PT) in HBV-DNA positive patients were significantly higher than those in HBV-DNA negative group( F=42. 693,18. 752,32. 692, 48. 225,all P=0. 000);and with the increase of the amount of virus,the level of the patients' index continued to increase. Conclusion For patients with chronic hepatitis B,the HBV-DNA level and the viral replication should be detected,and the liver function should be evaluated to observe the liver damage timely,thus to provide reference for clinical effective intervention.
ABSTRACT
Objective To assess the clinical effect and safety evaluation of Keluoxin capsule in the treatment of the patients with early diabetic nephropathy. Methods One hundred and forty-nine patients with early diabetic nephropathy were randomly divided into the treatment group and control group, 74 in each group. The control group was treated with Keluoxin placebo capsules (2 g every time, 2 times a day, oral) and Irbesartan (150 mg every time, once a day, oral) simultaneously; and thetreatment group was treated with Keluoxin capsules (2 g every time, 2 times a day, oral) and Irbesartan (150 mg every time, once a day, oral) simultaneously. Both groups were treated for 24 weeks. The clinical curative effect, the changes of blood sugar levels, TG, TC, LDL-C, HDL-C, BUN, Scr, 24 hUTP and 24 hUAE were assessed and compared, and the treatment safety of Keluoxin capsule was assessed. Results Compared with the control group, the markedly effective rate and total effective rate of treatment group increased significantly (χ2=9.208, P0.05). There was no adverse event between two groups. Conclusions The clinical effect of Keluoxin capsule can benefit the patients with early diabetic nephropathy.